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Summary
Alzheimer’s disease (AD) is the most common type of dementia. It
is the only one of the top ten causes of death in the USA for
which prevention strategies have not been developed. Although
AD has traditionally been associated with the deposition of
amyloid b plaques and tau tangles, it is becoming increasingly
clear that it involves disruptions in multiple cellular systems.
Therefore, it is unlikely that hitting a single target will result in
significant benefits to patients with AD. An alternative approach
is to identify molecules that have multiple biological activities
that are relevant to the disease. Fisetin is a small, orally active
molecule which can act on many of the target pathways
implicated in AD. We show here that oral administration of
fisetin to APPswe/PS1dE9 double transgenic AD mice from 3 to
12 months of age prevents the development of learning and
memory deficits. This correlates with an increase in ERK phos-
phorylation along with a decrease in protein carbonylation, a
marker of oxidative stress. Importantly, fisetin also reduces the
levels of the cyclin-dependent kinase 5 (Cdk5) activator p35
cleavage product, p25, in both control and AD brains. Elevated
levels of p25 relative to p35 cause dysregulation of Cdk5 activity
leading to neuroinflammation and neurodegeneration. These
fisetin-dependent changes correlate with additional anti-inflam-
matory effects, including alterations in global eicosanoid synthe-
sis, and the maintenance of markers of synaptic function in the
AD mice. Together, these results suggest that fisetin may provide
a new approach to the treatment of AD.
Key words: astrogliosis; ERK; eicosanoid; lipoxygenase;
oxidative stress; prostaglandin.
Introduction
Although Alzheimer’s disease (AD) is defined in terms of plaque and
tangle pathology, it is most frequently associated with other detrimental
events such as microvascular damage and inflammation (Schubert &
Maher, 2012). By far, the major risk factor for AD is old age (Herrup,
2010), and age-related decreases in cognitive function in both non-AD
and AD subjects involve alterations in multiple cellular processes.
Therefore, it is unlikely that hitting a single target will result in significant
benefits to patients with AD (Frautschy & Cole, 2010). This conclusion
has been largely borne out by the failure of numerous clinical trials for
single target drugs in AD (Golde et al., 2011). Nevertheless, current drug
research efforts continue to be almost exclusively focused on single
protein targets and the identification of small molecules that can
modulate these targets with high affinity (Schubert & Maher, 2012). An
alternative approach is to identify small molecules that have multiple
biological activities that are relevant to AD.
We have identified a small, orally active molecule, fisetin, which can
act on many of the target pathways implicated in AD (Maher, 2009).
Fisetin was originally identified in a screen for flavonoids that could
prevent oxidative stress-induced nerve cell death (Ishige et al., 2001). Of
the ~30 flavonoids tested in this study, fisetin was one of the most
potent. Additional studies showed that fisetin also possessed neuro-
trophic activity, a property that distinguished it from the other flavonoids
tested (Sagara et al., 2004). We then showed that fisetin could facilitate
long-term potentiation in hippocampal slices in an ERK-dependent
manner and that oral administration promoted memory in normal mice
(Maher et al., 2006). More recently, we demonstrated that fisetin was
effective at slowing death in multiple models of Huntington’s disease in
a partially ERK-dependent manner (Maher et al., 2011). Fisetin also has
anti-inflammatory activity both in vitro and in vivo (Gelderblom et al.,
2012). Furthermore, it can reduce Ab fibril formation in vitro (Kim et al.,
2005). Together, these observations indicate that fisetin has multiple
properties that together might be able to prevent the decline in brain
function associated with AD.
As fisetin improves memory and has in vivo anti-inflammatory and
in vitro neurotrophic and anti-amyloid properties, we investigated its
effects in an AD disease model, the APPswe/PS1dE9 double transgenic
AD mouse. The purpose of the study was to determine whether fisetin
could reduce AD-associated learning and memory deficits and to see
how these actions correlated with its effects on AD-related processes
implicated in disease progression including amyloid burden, gliosis,
oxidative damage, inflammatory pathways and their eicosanoid products
as well as dysregulation of the cyclin-dependent kinase 5 (Cdk5)
activator p35. The cleavage of p35 to p25 results in hyperactivation and
dysregulation of Cdk5 activity, and the accumulation of p25 has been
implicated as a causative factor in AD (Lopes et al., 2010). Importantly,
p25 overexpression is associated with inflammation and astrogliosis
along with synaptic damage (Muyllaert et al., 2008; Sundaram et al.,
2012). Together, our results demonstrate that fisetin, a compound that
activates multiple, well-defined neuroprotective pathways, may provide
a new approach to the treatment of AD.
Results
The APPswe/PS1dE9 double transgenic (AD) mice (Jankowsky et al.,
2001) used for these studies show significant plaque deposition by
8–9 months of age (Jankowsky et al., 2005) as well as clear cognitive
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impairment (Jankowsky et al., 2005). Therefore, it was initially asked
whether fisetin could reduce these changes. Two groups each of wild-
type and AD mice were used for these studies. Fisetin was fed to one set
of wild-type and one set of AD mice between the ages of 3 and
12 months in their food at 0.05%, resulting in a daily dose of
approximately 25 mg kg1. This dose of fisetin was chosen based on
earlier studies on fisetin and cognitive function in mice (Maher et al.,
2006).
We tested the performance in both the learning and memory arms of
the Morris water maze (MWM) at 9 months of age and then repeated
the memory arm in a 2-day version of the water maze (WM) (Gulinello
et al., 2009) at 12 months. At 9 months of age, wild-type mice showed
decreased times to find the hidden platform over the 5 days of the
MWM assay (Fig. 1A). Fisetin had no significant effect on the behavior of
the wild-type mice in the acquisition task. In contrast, the AD mice
showed very little learning over the 5 days of the acquisition task, while
the fisetin-fed AD mice behaved almost indistinguishably from the wild-
type mice in the acquisition task (Fig. 1A). In the probe test (Fig. 1B),
which specifically assays memory, the wild-type mice and the wild-type
mice fed fisetin both showed significant recall of the platform quadrant
spending >25% of their time in this quadrant. In contrast, the AD mice
showed no indication of memory, spending only 16% of their time in the
platform quadrant. As the platform quadrant is on the opposite side of
the tank from where the mice enter, it is not surprising that they spend
<25% of their time in this quadrant. However, the AD mice fed fisetin
showed clear evidence of memory improvement. Fisetin had no effect on
swim speeds (not shown).
As AD is a progressive disease, we tested the mice again at
12 months to determine whether fisetin continued to reduce memory
deficits. As we knew from previous studies that we could not repeat the
MWM on the same set of mice, we used an alternative version that only
tests memory (Gulinello et al., 2009) and addresses some of the
confounding factors that arise when testing older mice in the MWM. In
the 2 day WM, on day 1, mice are trained to find a visible platform using
four trials. All of our mice, regardless of genotype or diet, were able to
find the visible platform within 30 s by the last visible trial (Fig. 1C). This
result indicated that neither the genotype nor the diet affected the
animals’ ability to swim or to locate the visible platform. Thus, any
impairment in spatial memory seen with the 2 day WM will reflect a
cognitive deficit and not a lack of motivation or visual function. 24 h
after the final visible platform trial, the mice were tested in the same
tank but with the platform hidden. As shown in Fig. 1C, the escape
latency of the AD mice was significantly longer than that of the wild-type
mice, similar to what was reported for triple transgenic AD mice
(Gulinello et al., 2009). In contrast, the escape latency for the AD mice
fed fisetin was indistinguishable from that for the wild-type mice.
Another characteristic of AD is social disinhibition which can result in
inappropriate behavior in patients with AD. The elevated plus maze
(EPM), a rodent model of anxiety, is often used as a measure of
disinhibition in mice (Walf & Frye, 2007). The AD mice used in this study
were previously shown to exhibit increased time in the open arms in the
EPM (Pugh et al., 2007), which was interpreted as indicative of
disinhibition. As shown in Fig. 1D, we also found that the AD mice
spent significantly more time in the open arm than the wild-type mice.
This behavior was reversed in the mice fed fisetin.
Given the clear improvement in both cognitive and neuropsychiatric
behavior in the AD mice fed fisetin, we next asked what biochemical
changes might underlie these effects of fisetin.
As the AD mice are characterized by increases in amyloid-b (Ab
plaques), we first looked at plaque loads in sections of brains from these
mice. No significant differences in Ab plaque loads were seen (Fig. 1E).
We also looked at Ab levels in the radioimmunoprecipitation assay buffer
(RIPA) insoluble (100 000 g pellet) and soluble (RIPA supernatant)
fractions of the hippocampi of fisetin-fed and control AD mice. Neither
Ab1-40 nor Ab1-42 levels, as measured by ELISA, were altered in the RIPA
insoluble fraction in the animals fed fisetin relative to untreated animals
(Fig. 1F). However, fisetin treatment did significantly reduce the levels of
Ab1-40 but not Ab1-42 in the RIPA soluble fraction (Fig. 1G).
Previously, it was shown that fisetin is able to reduce markers of
oxidative stress in cell culture neuroprotection assays (Ishige et al., 2001)
and to induce ERK phosphorylation in cultured cells (Sagara et al., 2004)
and mouse hippocampal slices (Maher et al., 2006). Both increases in
oxidative stress (Sonnen et al., 2008) and decreases in ERK-dependent
signaling (Giovannini et al., 2008) have been implicated in decreases in
cognitive function in AD. Furthermore, ERK activation plays a key role in
synaptic plasticity and memory (Sweatt, 2004). Thus, we first looked at
fisetin’s effects on these parameters. As shown in Fig. 2A, fisetin
reduced oxidative stress in both control and AD mice as determined by
changes in protein carbonylation using the OxyBlot kit. Fisetin also
increased ERK phosphorylation both in wild-type and AD mice (Fig. 2B).
ERK activation induces the expression of p35, a neuron-specific
activator of Cdk5 (Desbarats et al., 2003). Cleavage of p35 to its
truncated form, p25, which results in the aberrant activation of Cdk5,
has been linked to disruptions in synaptic plasticity and integrity in AD
(Cruz & Tsai, 2004). While Cdk5 activation by p35 is associated with its
normal physiological activities, activation by the truncated form, p25,
abnormally stimulates Cdk5 activity. As ERK phosphorylation was altered
by fisetin, the effect of fisetin and AD on the levels of p35 and p25 in the
mouse hippocampus was assayed. While fisetin did not significantly alter
p35 levels in the hippocampi of the AD mice, it did prevent the highly
significant increase in p25 levels in AD mice and greatly reduced the p25/
p35 ratio in both wild-type and AD mice (Fig. 2C). Fisetin did not alter
the levels of Cdk5 in any mice (Fig. 2D). The Cdk5/p35 complex
modulates the activity of a variety of proteins, including synapsin 1 and
postsynaptic density protein 95 (PSD95), through phosphorylation. As
shown in Fig. 2E, PSD95 phosphorylation was reduced in the AD brains
and this was restored by fisetin. Fisetin also restored the levels of the
PSD95-associated protein drebrin (Fig. 2F). An elevation of drebrin above
control levels was also seen with the neurotrophic compound J147
(Chen et al., 2011).
Recently, using mice overexpressing p25 specifically in neurons, it was
shown that p25 induces neuroinflammation that is associated with
astrogliosis (Muyllaert et al., 2008; Sundaram et al., 2012). Thus, given
the effects of fisetin on p25 levels in the AD mice, we looked at glial
fibrillary acidic protein (GFAP) levels, a marker of astrogliosis, in both
wild-type and AD mice in the absence and presence of fisetin treatment.
As shown in Fig. 3, while AD had no effect on the number of astrocytes
in the hippocampus (Fig. 3B), it significantly increased both their area
and the intensity of GFAP staining (Fig. 3C,D). This alteration was largely
reversed by fisetin treatment. A fisetin-dependent reduction in GFAP
levels was also seen in the hippocampus of the AD mice by Western
blotting (Fig. 4A). Upregulation of cytosolic phospholipase A2 (cPLA2)
was found to play a key role in the astrogliosis seen in p25-
overexpressing mice (Sundaram et al., 2012). Consistent with this
observation, cPLA2 levels were significantly increased in the hippocampi
of AD mice but were restored to control values by fisetin treatment
(Fig. 4B). Cyclooxygenase 1 (Cox1) was also increased in the AD mice
(Fig. 4D) and this protein along with cyclooxygenase 2 (Cox2) and
12-lipoxygenase (12-LOX) was reduced by treatment with fisetin (Fig. 4E
and G). As Cox1 is constitutively expressed, the increase in Cox1 levels in
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the AD mice may be due to an increase in the number of Cox1-
producing cells such as microglia. The levels of inducible nitric oxide
synthase (iNOS) and 5-lipoxygenase (5-LOX) were not statistically
different between the groups (Fig. 4C and F).
To further elucidate the effects of fisetin on inflammation, we
conducted a detailed analysis of eicosanoid production in the wild-type
and AD mice with and without fisetin treatment using liquid chroma-
tography tandem mass spectrometry (Fig. 5). This approach generated
(A) (B)
(C) (D)
(E)
(G)
(F)
Fig. 1 Fisetin maintains learning and
memory in AD mice but does not affect
plaque number. (A) Performance of the
mice during the acquisition phase of the
MWM test. Nine-month-old AD mice failed
to learn the task over the 5-day testing
period, whereas fisetin-treated AD mice
learned to locate the submerged platform.
(B) Performance of the mice during the
memory phase of the MWM test. AD mice
did not spend a greater than random
percentage of their time in the quadrant
where the submerged platform was
previously located, whereas fisetin-treated
AD mice spent greater than random
amounts of time in the platform quadrant.
(C) Performance of 12-month-old mice
during the 2-day WM test. Although all the
mice learned to find the visible platform on
day 1, the AD mice did not remember
where the platform was located when it
was submerged on day 2, whereas
fisetin-treated AD mice did remember. (D)
12-month-old AD mice spend more time in
the open arm of the elevated plus maze, an
indicator of disinhibition, as compared with
fisetin-treated AD mice. Data represent
means  SD, n = 9–12 per group. Analysis
by one-way ANOVA followed by Tukey-
Kramer multiple comparisons post hoc test.
*P < 0.05 and **P < 0.01 relative to
control non-Tg mice. (E) 30 micrometer
thick coronal sections from 12-month-old
AD mice were stained with antibody 6E10,
and plaque counts in the hippocampus
were quantified using Image J software.
The average plaque counts for each mouse
group is expressed as the number of
plaques  SD (n = 6 per group; unpaired
t-test). Ab1-40 and Ab1-42 levels were
measured in the insoluble (100 000 g
pellet) (F) and RIPA soluble (G) hippocampal
fractions by ELISA in untreated AD mice
and AD mice fed fisetin. The results are
expressed as mean  SD, n = 6–8 per
group. Analysis by unpaired t-test.
*P < 0.05. AD, Alzheimer’s disease; MWM,
Morris water maze.
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global profiles consisting of over 160 individual eicosanoids many of
which were altered in AD and after fisetin treatment. Eicosanoids are a
class of bioactive lipid mediators derived from the metabolism of
polyunsaturated fatty acids, namely arachidonic acid (AA), by COXs,
LOXs, cytochrome P450s, and nonenzymatic pathways (Buczynski et al.,
2009). They are known to be potent endogenous regulators of the
inflammatory response in the periphery but are much less well studied in
the brain. We found that AD increased the production of the pro-
inflammatory thromboxanes TXB1 and TXB2 and this was partly
prevented by fisetin. On the other hand, fisetin increased production
of prostaglandin D2 (PGD2) and its nonenzymatic anti-inflammatory
products prostaglandin J2 (PGJ2) and 15-deoxy-PGD2 (15d-PGD2). The
effects of AD and fisetin on LOX metabolites are also shown in Fig. 5.
While AD did not have any significant effect on the levels of LOX
metabolites, fisetin significantly reduced the levels of pro-inflammatory
5-hydroxyeicosatetraenoic acid (5-HETE) and 12-hydroxyeicosatetraenoic
acid (12-HETE), the primary metabolites of 5-LOX and 12-LOX, respec-
tively, in the AD mice. Furthermore, this analysis showed that fisetin
strongly reduced the levels of multiple monohydroxydocosahexaenoic
acids (HDoHE), metabolic derivatives of docosahexaenoic acid (DHA), in
the AD mice. These can be generated by either auto-oxidation of DHA or
enzymatic metabolism of DHA via LOX pathways (Reynaud et al., 1993).
Eicosanoids are both products and regulators of the innate immune
system whose dysregulation has been implicated in AD (for review see
Butchart & Holmes, 2012). Therefore, we looked at the RNA expression
of components of the innate immune system in the brains of our mice
and found that several members of the complement and the toll-like
receptor (TLR) pathways were significantly upregulated in the AD mice
(Table 1). While fisetin did not affect the expression of any of the
complement markers, it did prevent the increase in CD40 and lowered
the expression of some of the TLRs that were elevated in the AD mice.
We also evaluated the effects of long-term feeding of fisetin on the
health of the animals. No significant differences in body weights were
seen between the groups. Following sacrifice, multiple tissues (lungs,
spleen, liver, kidneys, heart, stomach, intestine, testes, and ovary) were
examined using standard toxicological pathology criteria and no toxicity
was associated with fisetin treatment. Furthermore, fisetin showed no
toxicity at doses up to 2 g kg1 in an acute toxicity assay and was
negative in the Ames test.
Discussion
The above data show that oral administration of the flavonoid fisetin
prevents the cognitive and neuropsychiatric problems that develop as a
consequence of AD. A major nexus for the effects of fisetin in the AD
mice appears to be the Cdk5 activator p35 (Fig. 6). Importantly, fisetin
can induce ERK activation both in vitro (Sagara et al., 2004; Maher
et al., 2006) and, as shown in Fig. 2, in mice and ERK activation can
(A) (B) (C)
(D) (E) (F)
Fig. 2 Fisetin reduces oxidative stress, increases ERK activation, and maintains p35. (A) Fisetin reduces protein carbonylation, a marker of oxidative stress, in hippocampal
extracts of non-Tg and AD mice. (B) Fisetin increases ERK activation in non-Tg and AD mice. (C) Fisetin reduces the cleavage of the Cdk5 activator p35 to
pro-neurodegeneration p25. (D) Fisetin does not alter Cdk5 levels. (E) The phosphorylation of the p35 substrate PSD95, which correlates with synapse efficacy, is
reduced in AD mice and maintained by fisetin. (F) Fisetin increases the synaptic spine marker drebrin in AD mice. Representative Western blots are shown. Data
represent means  SD, n = 9–12 per group. Analysis by one-way ANOVA followed by Tukey-Kramer multiple comparisons post hoc test. *P < 0.05, **P < 0.01 and
***P < 0.001 relative to control non-Tg mice or AD mice. AD, Alzheimer’s disease; PSD95, postsynaptic density protein 95; Cdk5, cyclin-dependent kinase 5.
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(A)
(B) (C)
(D)
Fig. 3 Fisetin reduces astrocytic reactivity
in the brains of AD mice. (A) Representative
images of GFAP immunostaining in the
hippocampus. The graphs show
quantification of (B) the number of
astrocytes per mm2, (C) the average
astrocyte area (lm2), and (D) the intensity
of GFAP staining in relation to non-Tg mice.
Scale bar: 10 lm. Data represent
means  SEM, n = 3 per group (4–5 slices
per brain). Analysis by one-way ANOVA
followed by Tukey-Kramer multiple
comparisons post hoc test. *P < 0.05 and
**P < 0.01 relative to control non-Tg mice
or AD mice. GFAP, glial fibrillary acidic
protein.
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induce p35 expression (Desbarats et al., 2003). Furthermore, in cells,
both GSH and oxidized GSH (GSSG) were found to inhibit the activity of
calpain (Rackoff et al., 2001), the protease implicated in the cleavage of
p35 to p25. Fisetin is able to maintain GSH levels under conditions of
oxidative stress (Ishige et al., 2001). Thus, fisetin may be particularly
effective at maintaining p35 because of its ability to both stimulate ERK
activity as well as to reduce p35 cleavage. This in turn may contribute to
the maintenance of markers of synaptic function such as PSD95 and
drebrin and the decrease in markers of neuroinflammation. Although
another of the consequences of p35 cleavage in AD can be an induction
of tau phosphorylation (Lopes et al., 2010), no increases in tau
phosphorylation were seen in the AD mice in our hands (not shown),
so it was not possible to evaluate the effects of fisetin on this parameter.
Consistent with a recent study on the consequences of p25-
overexpression in mice (Sundaram et al., 2012), astrogliosis was seen
in the AD mouse brains. It was suggested that this was dependent on the
p25-mediated activation of cPLA2. We detected an increase in cPLA2
levels in the AD mice which, along with astrogliosis, was prevented by
(A) (B) (C)
(D) (E) (F)
(G)
Fig. 4 Fisetin reduces the protein expression of markers of inflammation in the AD mice. (A) GFAP, (B), PLA2c, (C), iNOS (D), Cox1 (E) Cox2, (F) 5-LOX and (G)
12-LOX. Representative Western blots are shown. Data represent means  SD, n = 9–12 per group. Analysis by one-way ANOVA followed by Tukey-Kramer multiple
comparisons post hoc test. *P < 0.05 and ***P < 0.001 relative to control non-Tg mice or AD mice. AD, Alzheimer’s disease; GFAP, glial fibrillary acidic protein; iNOS,
inducible nitric oxide synthase; Cox1, cyclooxygenase 1.
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Fig. 5 Fisetin modulates the metabolism of AA and DHA eicosanoid derivatives in AD mice. Data represent means  SEM, n = 6 per group. Analysis by one-way ANOVA
followed by Newman–Keuls post hoc test. *P < 0.05 and **P < 0.01 relative to control non-Tg mice or AD mice. AD, Alzheimer’s disease.
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fisetin treatment. cPLA2 levels were also shown to be increased in
human AD brains along with other markers of inflammation including
Cox2 (Rao et al., 2011). Furthermore, both astrocytes and microglia
have been reported to be activated in AD and their activation is
implicated in the loss of nerve cell function (Rao et al., 2011). In
particular, activation of astrocytes results not only in the production of
pro-inflammatory cytokines but also in a decrease in their normal role as
guardians of nerve cell function (Steele & Robinson, 2012).
The other key finding from this study is that both AD and fisetin alter
eicosanoid biosynthesis in the brain with the overall result being a
reduction in pro-inflammatory products by fisetin. TXB2 and TXB1 were
found significantly elevated in the AD brains and were partly reduced by
fisetin. The thromboxane pathway is implicated in platelet aggregation,
adhesion, and vascular contraction during inflammation (Hardwick
et al., 2013). This is of relevance given the prothrombotic effect of
TXs and the link between thrombosis and vascular pathology in AD
(Cortes-Canteli et al., 2010). Thus, fisetin has anti-inflammatory effects
at multiple levels.
The increased production of PGD2 and its products PGJ2 and 15d-
PGD2 by fisetin is of particular interest because these prostaglandins
have potent anti-inflammatory effects in brain microglia (Yoon et al.,
2008) including down regulation of iNOS, a known effect of fisetin
(Gelderblom et al., 2012). Historically, PGD2 was regarded as a pro-
inflammatory mediator but a potentially anti-inflammatory role is now
also recognized (Scher & Pillinger, 2009). It is unclear what determines
Table 1 RNA quantitative analysis showing that the complement and the TLR inflammatory pathways are activated in the AD mice
Wt Wt+Fis AD AD + Fis
C1qa 2000.56  138.3 2026.48  115.42 4041.51  477.58* 3522.79  435.1*
C1qb 3172.4  195.47 3868.31  253.55 7441.85  273.81*** 7475  571.93***
C1r 321.68  4.15 362.45  35.88 343.16  12.46 340.72  12.63
C1s 52.82  3.22 53.57  9.15 64.68  3.83 60.42  5.5
C2 103.61  3.37 102.92  7.41 105.55  14.41 118.12  3.99
C3 N.d. N.d. N.d. N.d.
C3ar1 142.47  7.12 153.09  16.95 416.54  35.83*** 411.6  38.6***
C4a 821.5  55.47 972.85  218.94 3018.03  210.14*** 2792.64  195.29***
C6 N.d. N.d. N.d. N.d.
C7 N.d. N.d. N.d. N.d.
C8a N.d. N.d. N.d. N.d.
C8b N.d. N.d. N.d. N.d.
C9 N.d. N.d. N.d. N.d.
Cfb 33.33  5.15 35.18  8.77 64.56  4.52* 63.2  2.76*
Cfd N.d. N.d. N.d. N.d.
Cd55 220.24  12.18 174.02  0.85* 161.03  19.94* 169.83  7.77*
Tlr1 14.96  3.41 15.94  2.89 35.68  7 36.94  10.01
Tlr2 47.87  3.83 41.91  2.59 83.2  7.96** 71.15  5.97*
Tlr3 517.17  8.06 509.25  26.77 538.37  9.86 534.04  24.49
Tlr4 86.89  3.85 88.58  8.63 105.37  2.22 103.25  9.07
Tlr5 N.d. N.d. N.d. N.d.
Tlr6 84.89  17.99 81.33  14.43 87.43  11.41 130.68  12.47
Tlr7 100.48  6.93 94.82  8.1 186.99  18.57** 163.26  16.82*
Myd88 90.8  2.48 112.52  6.82 140.61  9.31** 131.9  9.69*
Nfkb1 514.78  13.91 507.57  18.96 539.09  8.79 523.12  11.26
Nos2 14  1.8 15.23  3.64 25.09  2.95 18.88  3.46
Tgfb1 320.62  28.64 282.07  22.95 478.88  33.67** 460.92  25.97**
Tgfb2 527.99  27.72 490.25  20.36 498.92  55.55 485.01  27.39
Tgfb3 481.06  19.57 430.96  23.11 459.16  5.89 408.42  10.89
Tgfbr1 1130.43  25.59 984.71  24.14** 1295.7  45.64** 1308.75  11.82**
Cd40 16.71  2.52 24.97  0.99 34.93  2.87** 25.22  2.32‡
Cd401g N.d. N.d. N.d. N.d.
Data represent means  SEM, n = 3 per group. Analysis by one-way ANOVA followed by Newman–Keuls post hoc test.
*P < 0.05, **P < 0.01, ***P < 0.001 relative to control non-Tg mice or ‡P < 0.05 relative to AD mice.
N.d., Not detected; TLR, toll-like receptor; AD, Alzheimer’s disease.
Fig. 6 Summary of the protective mode of action of fisetin in the AD mice. AD,
Alzheimer’s disease.
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PGD2’s inflammatory status, but our data showing an improvement in
cognitive performance and a reduction in the expression levels of pro-
inflammatory markers in the AD mice by fisetin suggest that the
increased levels of PGD2 and its metabolites might be associated with
the anti-inflammatory action of fisetin in the brain. Furthermore, PGD2
was reported to stimulate ERK activation (Choi et al., 2011), which is in
accordance with the enhanced ERK phosphorylation seen in both Wt
and AD mice treated with fisetin. Whether ERK activation can, in turn,
modulate the production of PGD2 and its metabolites remains to be
addressed. Importantly, hematopoietic PGD synthase (HPGDS), a mem-
ber of r-class of glutathione-S-transferases, has the ability to convert
PGH2 into PGD2 in the presence of GSH (Hardwick et al., 2013). Given
that fisetin is able to maintain GSH levels under conditions of oxidative
stress (Ishige et al., 2001), it might be that the increase in PGD2 and its
derivatives in mice treated with fisetin is in part mediated by the
maintenance of GSH levels in the brain, thereby affecting the activity of
PGD synthase. In contrast with lipocalin PGD synthase, which also
converts PGH2 into PGD2 but is GSH-independent (Hardwick et al.,
2013), HPGDS is expressed in immune and inflammatory cells. Impor-
tantly, HPGDS is upregulated in microglia and astrocytes surrounding Ab
plaques in human patients with AD and in an AD mouse model (Mohri
et al., 2007).
Fisetin has previously been shown to inhibit 5, 12 and 15-LOXs in cell-
based assays (for review see Maher, 2009). However, whether it could
also do so in vivo was not known. Both 5-LOX and 12-LOX metabolites
induce activation of NF-jB and the expression of pro-inflammatory
cytokines (Hardwick et al., 2013). The results shown in Fig. 5 in
combination with the protein expression data shown in Fig. 4 clearly
indicate that fisetin is able to inhibit both 5-LOX and 12-LOX in vivo, at
least in the context of AD.
HDoHEs are metabolic derivatives of DHA generated by either auto-
oxidation of DHA or enzymatic metabolism of DHA via the LOX
pathways (Reynaud et al., 1993). Fisetin had a potent inhibitory effect
on several of the HDoHEs, which is in accordance with the anti-oxidative
potential of fisetin and its inhibitory properties on the LOXs.
Analysis of RNA expression showed that both the complement and
TLR pathways were activated in the AD mice. This is of particular
relevance given that the complement system is also activated in human
patients with AD but that it is thought to be part of a neuroprotective
response that helps clear apoptotic cells and Ab peptide (Benoit et al.,
2013). Therefore, there is a component of the innate immune system
that must remain turned on and is beneficial in the context of AD. The
fact that fisetin did not alter this system could be of therapeutic
significance. Similarly, the relevance of some TLRs to the clearance of Ab
from the brain of AD mouse models has been demonstrated (Landreth &
Reed-Geaghan, 2009). Specifically, TLR2 and TLR4 have been shown to
mediate the activation of microglia which take up and clear Ab from the
brain (Landreth & Reed-Geaghan, 2009). However, the innate immune
system is a double-edged sword and if a persistent inflammatory
response exists, as in patients with AD, it may contribute to and
exacerbate the pathology. In this context, activation of TLR4 robustly
stimulates eicosanoid biosynthetic pathways, thereby further contribut-
ing to local inflammation (Quehenberger & Dennis, 2011). Our data
show the upregulation of several TLRs in the AD mice. Interestingly,
although not statistically significant, fisetin appears to lower the levels of
these TLRs. Fisetin also significantly prevented the AD-dependent
increase in CD40 which is known to potentiate TLR signaling and is
found associated with AD (Giunta et al., 2010).
Fisetin was also able to reduce protein carbonylation, a marker of
oxidative stress. Increases in oxidative stress have long been associated
with both mouse models and human AD (Sonnen et al., 2008) but the
exact mechanisms underlying this increase are still not clear. The results
presented here suggest that the increases in oxidative stress are more
likely to be associated with the increases in neuroinflammation rather
than Αb levels as while fisetin had no effect on Ab plaque load and only
a modest effect on soluble Ab1-40 levels, it significantly reduced multiple
markers of neuroinflammation in the AD mice. A key role for
neuroinflammation in cognitive dysfunction in AD mice is supported
by previous studies (Wirths et al., 2010).
Several recent epidemiological studies have provided evidence that
higher consumption of dietary flavonoids and especially flavonols, the
group to which fisetin belongs, is associated with lower rates of
dementia (Beking & Vieira, 2010; Kesse-Guyot et al., 2011). These
studies lend support to our results with fisetin in AD mice reported
here.
Although p25 and the aberrant activation of Cdk5 have been
suggested as therapeutic targets for the treatment of AD, it has not
been clear how to achieve this. Inhibitors of Cdk5 were recently found
to increase the levels of BACE1, the enzyme that initiates production of
Ab, suggesting that these compounds may not be useful for the
treatment of AD (Sadleir & Vassar, 2012). In contrast, fisetin is a natural
product that is clearly able to prevent the generation of p25 in the
brains of AD mice and therefore has the potential to do so in humans.
Furthermore, fisetin has additional properties including anti-inflamma-
tory activity and the ability to reduce oxidative stress which occurs in all
neurodegenerative diseases. In addition, as shown here, fisetin can
modulate eicosanoid production promoting an overall anti-inflammatory
profile. Together, these properties, and the fact that it is an apparently
safe natural product, make fisetin a particularly attractive compound for
the treatment of AD. Finally, our results suggest that analysis of
eicosanoid profiles might provide a powerful tool in the future when
assessing disease progression in disease models and human patients
with AD.
Experimental procedures
huAPPswe/PS1DE9 transgenic mice
The AD transgenic mice (line 85; a generous gift of Dr. J.L. Jankowsky)
have been previously characterized (Jankowsky et al., 2001). These mice
carry two transgenes, the mouse/human chimeric APP/Swe, linked to
Swedish FAD and human PS1ΔE9. At 3 months of age, male transgenic
mice and their wild-type littermates were fed a high fat diet (Harlan
Teklad, Madison, WI, USA) with and without fisetin (0.05%). Food
consumption was measured weekly, and there were no significant
differences between the groups. These studies were approved by the
Salk Institute IACUC.
Behavioral assays
Morris water maze
Spatial learning and memory were determined in 9-month-old AD
transgenic mice fed fisetin for the previous 6 months using the Morris
water maze (Vorhees & Williams, 2006). The MWM procedure was
four trials per day for five consecutive days. For each trial, mice were
placed in the pool (water temperature = 27 °C) at one of four start
locations. The starting locations were separated by 90° and mice
started a trial once from each of the four possible start locations on
each day. The latency to find and mount the hidden platform was
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used as the primary dependent variable. Swimming speeds were
recorded to assess fisetin-induced motor effects. Mice were given a
maximum of 50 s to find the hidden platform. If the mice failed to
find the platform after 50 s, they were placed on the platform by the
experimenter. All mice remained on the platform for 15 s before
being placed in a heated incubator (30 °C) between trials. Personnel
evaluating animals in the MWM were blinded to the genotype and
diet of each animal. A mean daily latency to find the goal platform
during MWM testing was computed for each mouse. On day 6, a 60-
s probe test was performed in which the platform was removed and
the time spent in the quadrant where the platform was previously
located was determined. Mice were disqualified if they exhibited
excessive floating or thigmotaxis.
Two day water maze
Spatial memory was determined in 12-month-old AD transgenic mice
fed fisetin for 9 months using the 2-day water maze adapted from
(Gulinello et al., 2009). The setup was the same as for the MWM. On
day 1 of the 2 day WM procedure, the mice were trained to find a visible
platform that remained in the same location for the four trials using cues
located around the pool within a 180-s time frame. There were four
visible platform trials (V1–V4) where the last visible platform trial of a
mouse was considered the baseline. Mice were disqualified if they failed
to reach the platform within 30 s in V4. On day 2, 24 h following the
last visible platform trial, the mice were tested in a hidden platform trial
for up to 180 s. The time it took for each mouse to find the hidden
platform was measured as escape latency. Swimming speeds were
recorded to assess fisetin-induced motor effects. All trials were recorded
using the EthoVision software (Noldus, Leesburg, VA, USA), and statistics
were computed using GraphPad Instat software (GraphPad, La Jolla, CA,
USA).
Elevated plus maze
The EPM analyzes the anxiety response of mice and relies upon the
tendency of mice to have a fear of heights and to navigate toward dark
enclosed spaces and remain there (Walf & Frye, 2007). Mice are
habituated to the room 24 h before testing. Mice are also habituated to
the maze for 2 min before testing by placing them in the center of the
maze and blocking entry to the arms. Mice are then tested in the maze
for a 5-min period and a video-tracking system (Noldus EthoVision)
tracks and records the behavior of the mice. Anxiety of mice is
measured by comparing the time spent on the open arms to time spent
on the closed arms. Statistics were computed using GraphPad Instat
software.
Tissue preparation and immunoblotting
Hippocampal tissue samples were homogenized in 10 volumes of RIPA
lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 0.1% sodium dodecyl
sulfate, 0.5% deoxycholate, and 1% NP40) containing a cocktail of
protease and phosphatase inhibitors. Samples were sonicated (2 9 10 s)
and centrifuged at 100 000 g for 60 min at 4 °C. Protein concentra-
tions in the cell extracts were determined using the BCA protein assay
(Pierce, Rockford, IL, USA). For SDS-PAGE, 20 lg of protein was used.
All samples were separated using 10 or 12% Criterion XT Precast Bis-
Tris Gels (Bio-Rad, Hercules, CA, USA). Proteins were transferred to
nitrocellulose membranes and the quality of protein measurement,
electrophoresis and transfer checked by staining with Ponceau S (Sigma-
Aldrich, St. Louis, MO, USA). Membranes were blocked with 5% skim
milk in TBS-T (20 mM Tris buffer pH 7.5, 0.5 M NaCl, 0.1% Tween 20)
for 1 h at room temperature and incubated overnight at 4 °C in the
primary antibody diluted in 5% BSA in TBS/0.05% Tween 20. The
primary antibodies used were mouse anti-phospho-ERK (#9106, 1/
1000), rabbit anti-ERK (#9102, 1/1000), rabbit anti-cPLA2 (#5249, 1/
1000), rabbit anti-Cox1 (#4841, 1/1000), rabbit anti-Cox2 (#4842, 1/
1000), rabbit anti-p35/25 (#2680, 1/1000), rabbit anti-phospho
(tyr340)-PSD95 (#2930, 1/1000), rabbit anti-PSD-95 (#2507, 1/1000)
and HRP-conjugated rabbit anti-actin (#5125, 1/20,000) from Cell
Signaling (Beverly, MA, USA); rabbit anti-GFAP (#AD5804, 1/5000) from
Millipore (Billerica, MA, USA); mouse anti-iNOS (#610431, 1/1000) and
mouse anti-5-LOX (#610694, 1/1000) from BD Biosciences (San Jose,
CA, USA); rabbit anti-12-LOX (#160304, 1/1000) from Cayman (Ann
Arbor, MI, USA) and mouse antidrebrin (#ab12350, 1/1000) from
Abcam (Cambridge, UK). Protein oxidation was assessed using the
OxyBlot kit (Millipore) according to the manufacturer’s instructions.
Subsequently, blots were washed in TBS/0.05% Tween 20 and
incubated for 1 h at room temperature in horseradish peroxidase-goat
anti-rabbit or goat anti-mouse (Bio-Rad) diluted 1/5000 in 5% skim milk
in TBS/0.1% Tween 20. After additional washing, protein bands were
detected by chemiluminescence using the SuperSignal West Pico
Substrate (Pierce). For all antibodies, the same membrane was reprobed
for actin or an antiserum reacting with the total protein. Autoradio-
graphs were scanned using a Bio-Rad GS800 scanner. Band density was
measured using the manufacturer’s software. Proteins were normalized
to actin band density. Phosphoprotein levels were normalized to total
protein expression. ANOVA with the Tukey’s post hoc test was used to
determine differences between means for Western blot analysis.
Immunohistochemistry
Brains were fixed with 4% paraformaldehyde in 100 mM sodium
tetraborate, pH 9.5, for 3 h, cryoprotected with 20% sucrose-
potassium-PBS (KPBS), and cryostat sectioned into coronal (30 lm)
sections. Sections were submerged in 0.3% H2O2 for 10 min to
eliminate endogenous peroxidase activity and treated with 1% borate
to eliminate free paraformaldehyde. Sections were incubated with
primary antibody in 0.3% Triton X-100 in KPBS plus 2% filtered serum
or BSA overnight at 4 °C, and with primary antibodies (1:1000) in
0.3% Triton X-100 for 1 hr at room temperature. After incubation
with secondary antibody and ABC reagent (Vector Laboratories,
Burlingame, CA, USA), sections were developed using metal-enhanced
DAB solution. Sections were mounted to slides, dried, dehydrolyzed,
treated with xylene, and covered using dibutyl phthalate xylene. Images
were captured by a Zeiss digital camera connected to a Zeiss VivaTome
microscope, and image analysis on sections was performed using
Axiovision software.
Quantification of amyloid plaque burden was based on the image
captured by immunohistochemical staining with antibody 6E10. Sections
of each mouse cortex and hippocampus were imaged together, and the
areas and densities of the plaques in the hippocampus only were
measured by the Image J software (NIH, Bethesda, MD, USA). The total
counts of Ab plaques in sections per six mouse brains of each group
were determined in an unbiased fashion.
Quantification of astrogliosis was based on the image captured by
immunohistochemical staining with GFAP antibody. Sections of each
mouse hippocampus were imaged together and the number of
astrocytes per mm2, average astrocyte area per lm2, and relative
intensity of GFAP staining were measured by the Image J software (NIH).
Total counts in 4–5 sections per three mouse brains of each group were
determined in an unbiased fashion.
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Ab ELISA
Ab 1-40 and 1-42 levels in hippocampal lysates were analyzed using the
Ab1-40 and Ab1-42 ELISA kits from Invitrogen (# KHB3481 and #
KHB3442, respectively; Carlsbad, CA, USA) according to the manufac-
turer’s instructions.
Eicosanoid analysis
Eicosanoid extraction
All solvents were of chromatography purity. Eicosanoids used for primary
standards in standard curves as well as their deuterated analogs were
from Cayman Chemicals and Biomol (Enzo Life Science, Farmingdale,
NY, USA). For extraction, 5 mg of brain tissue (entorhinal cortex) was
supplemented with a cocktail consisting of 26 deuterated internal
standards, homogenized with 500 lL 10% methanol on ice and briefly
sonicated. Samples were then purified by solid phase extraction on
Strata-X columns (Phenomenex, Torrance, CA, USA) following the
activation procedure provided by the distributor. Samples were eluted
with 1 mL of 100% methanol, the eluent was dried under vacuum and
dissolved in 50 lL of buffer A consisting of 60/40/0.02 water/acetoni-
trile/acetic acid = 60/40/0.02 (v/v/v) and immediately used for analysis.
Reverse-phase liquid chromatography and mass spectrometry
Eicosanoids were analyzed as previously described (Quehenberger
et al., 2011). Briefly, eicosanoids were separated by reverse-phase
chromatography using a 1.7 lM 2.1 9 100 mm BEH Shield Column
(Waters, Milford, MA, USA) and an Acquity UPLC system (Waters). The
column was equilibrated with buffer A, and 5 lL of sample was
injected via the autosampler. Samples were eluted with a step gradient
to 100% buffer B consisting of acetonitrile/isopropanol = 50/50 (v/v).
The liquid chromatography effluent was interfaced with a mass
spectrometer, and mass spectral analysis was performed on an AB
SCIEX 6500 QTrap mass spectrometer equipped with an IonDrive Turbo
V source (AB SCIEX, Framingham, MA, USA). Eicosanoids were
measured using multiple reaction monitoring (MRM) pairs with the
instrument operating in the negative ion mode. Collisional activation of
the eicosanoid precursor ions was achieved with nitrogen as the
collision gas, and the eicosanoids were identified by matching their
MRM signal and chromatographic retention time with those of pure
identical standards.
Quantitation of eicosanoids
Eicosanoids were quantified by the stable isotope dilution method.
Briefly, identical amounts of deuterated internal standards were added
to each sample and to all the primary standards used to generate
standard curves. To calculate the amount of eicosanoids in a sample,
ratios of peak areas between endogenous eicosanoids and matching
deuterated internal eicosanoids were calculated. Ratios were converted
to absolute amounts by linear regression analysis of standard curves
generated under identical conditions. Currently, we can quantify over
150 eicosanoids at sub-fmole levels.
RNA analysis
The nCounter GX Mouse Inflammation Kit (Nanostring, Seattle, USA)
was used to measure a comprehensive set of 179 inflammation related
mouse genes and six internal reference genes. RNA was isolated from
occipital, parietal, and temporal cortices using the RNeasy mini kit
(Qiagen, Gaithersburg, MD, USA) following the manufacturer’s instruc-
tions and RNA analysis performed by Nanostring.
Toxicological analysis
Tissues from wild-type control and fisetin-treated mice were sent to
Colorado Histo-Prep (Fort Collins, CO, USA) for histopathological
evaluation. A 2-day acute toxicity assay was performed by Absorption
Systems (San Diego, CA, USA). The Ames test using strain TA100 was
performed as described (Maron & Ames, 1983).
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